DP
JAZZ icon

Diadema Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Diadema Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-50,000
Closed -$6.59M – 167
2025
Q3 		$6.59M Buy
+50,000
New +$6M 1.69% 18
2025
Q2 		– Sell
-100
Closed -$12.4K – 113
2025
Q1 		$12.4K Buy
+100
New +$13K ﹤0.01% 101

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Diadema Partners's JAZZ Position: Q2 2026 in Review

Diadema Partners sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2026, closing a stake of 54,755 shares — an estimated $10.4M sold.

Diadema Partners first reported a position in JAZZ in Q4 2024 and held it in 5 quarters. The position peaked at $11.1M in Q2 2025. 647 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • Diadema Partners reported no remaining Jazz Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Diadema Partners sold 54,755 Jazz Pharmaceuticals shares in Q2 2026, an estimated $10.4M.
  • Diadema Partners first reported a position in Jazz Pharmaceuticals in Q4 2024 and held it in 5 quarters.
  • Diadema Partners's Jazz Pharmaceuticals position peaked at $11.1M in Q2 2025.
  • 647 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Diadema Partners's 13F filing for Q2 2026, filed 14 Aug 2026.